Procedure guideline for brain death scintigraphy.

Phase I/II 90 Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma

2000 • 235 citations

Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.

2003 • 215 citations

Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach.

2003 • 174 citations

Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody.

2002 • 157 citations

Update on hybrid conjugate-view SPECT tumor dosimetry and response in 131I-tositumomab therapy of previously untreated lymphoma patients.

2003 • 76 citations

The role of ¹²³I‐diagnostic imaging in the follow‐up of patients with differentiated thyroid carcinoma as compared to ¹³¹I‐scanning: avoidance of negative therapeutic uptake due to stunning

2001 • 57 citations